Clinical trial

Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in…

NCT00230971 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed

Key facts

NCT number NCT00230971
Title Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection (cIAI)
Official title A Multicenter, Open-Label, Randomized Comparative Study of Tigecycline vs Ceftriaxone Sodium Plus Metronidazole for the Treatment of Hospitalized Subjects With Complicated Intra-abdominal Infection
Lead sponsor Wyeth is now a wholly owned subsidiary of Pfizer, Industry
Status Completed
Phase Phase 4
Study type Interventional
Conditions Appendicitis, Cholecystitis, Diverticulitis, Intra-Abdominal Abscess, Intra-Abdominal Infection, Peritonitis
Intervention type Drug
Interventions tigecycline, ceftriaxone plus metronidazole
Enrollment 473
Start date Oct 1, 2005
Primary completion Sep 1, 2008
Completion Sep 1, 2008
First posted Oct 3, 2005
Last update posted Feb 25, 2013
Countries Australia, China, Denmark, Finland, France, Germany, Greece, Hong Kong, India, Italy, Philippines, Portugal and 7 more

At a glance

  • Yes Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies